Physician profile
Philma B Opinaldo
NPI 1023128840
$1,535.76
in general payments reported to CMS, 2019-2025
26 companies · $56.55 in 2025
The $56.55 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,130 · 2020: $59.90 · 2021: $49.78 · 2022: $170 · 2023: $16.20 · 2024: $53.62 · 2025: $56.55.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $69.82 · Education: $56.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $69.82 |
| Education | $56.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $263.50 | 2019 | |
| Supernus Pharmaceuticals, INC. | $198.07 | 2019-2021 | |
| Novo Nordisk INC | $172.90 | 2019-2022 | |
| Astellas Pharma US INC | $140.75 | 2019-2022 | |
| Glaxosmithkline, LLC. | $108.53 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.34 | 2019-2025 | Jardiance |
| Abbvie INC. | $92.86 | 2021-2024 | |
| Lilly USA, LLC | $80.16 | 2019-2022 | |
| Amgen INC. | $48.68 | 2019-2024 | Repatha, Otezla |
| Sanofi-Aventis U.S. LLC | $40.60 | 2019 | |
| Amarin Pharma, INC. | $35.81 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.99 | 2019 | |
| Eisai INC. | $28.17 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $27.78 | 2019 | |
| Pfizer INC. | $24.18 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $19.26 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.73 | 2019 | |
| Sumitomo Pharma America, INC. | $16.20 | 2023 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $14.70 | 2019 | |
| Circassia INC. | $13.52 | 2019 | |
| Scilex Pharmaceuticals INC. | $13.26 | 2019 | |
| Merck Sharp & Dohme LLC | $12.50 | 2019 | |
| Assertio Therapeutics, INC. | $12.33 | 2019 | |
| Ironwood Pharmaceuticals, INC | $12.12 | 2019 | |
| Grifols USA, LLC | $11.58 | 2019 | |
| Cardiovascular Systems INC. | $2.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philma Opinaldo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.